Optimizing resection for "responding" hepatic metastases after neoadjuvant chemotherapy

J Surg Oncol. 2010 Dec 15;102(8):1002-8. doi: 10.1002/jso.21694.

Abstract

Fifty percent of patients with colorectal cancer will develop metastases at some time during their disease, with the liver being the most common site. Recent advances in the treatment of metastatic colorectal cancer have led to a change in treatment paradigm. What follows is a review of the surgical management of hepatic colorectal metastases responding to neoadjuvant chemotherapy. In addition, the complexity of treating patients with "disappearing" colorectal liver metastases is discussed.

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Colorectal Neoplasms / drug therapy
  • Colorectal Neoplasms / pathology
  • Colorectal Neoplasms / secondary
  • Colorectal Neoplasms / surgery*
  • Hepatectomy / methods*
  • Humans
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / pathology
  • Liver Neoplasms / secondary
  • Liver Neoplasms / surgery*
  • Neoadjuvant Therapy
  • Neoplasm Staging

Substances

  • Antineoplastic Agents